Adjuvant Gefitinib May Boost Disease-free Survival in EGFR-mutant NSCLC Adjuvant Gefitinib May Boost Disease-free Survival in EGFR-mutant NSCLC

Gefitinib may prolong disease-free survival, compared with cisplatin-based adjuvant chemotherapy, in patients with resected stage II-IIIA EGFR-mutant non-small-cell lung cancer (NSCLC), according to results from the ADJUVANT/CTONG1104 randomized trial.Reuters Health Information
Source: Medscape Pathology Headlines - Category: Pathology Tags: Hematology-Oncology News Source Type: news